CN107281473A - 一种修护宫腔粘膜的组合物及其制备方法 - Google Patents
一种修护宫腔粘膜的组合物及其制备方法 Download PDFInfo
- Publication number
- CN107281473A CN107281473A CN201710319042.5A CN201710319042A CN107281473A CN 107281473 A CN107281473 A CN 107281473A CN 201710319042 A CN201710319042 A CN 201710319042A CN 107281473 A CN107281473 A CN 107281473A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- maintenance
- uterine cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 20
- 238000012423 maintenance Methods 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 241000207925 Leonurus Species 0.000 claims abstract description 17
- 229920001661 Chitosan Polymers 0.000 claims abstract description 16
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 16
- 108090000790 Enzymes Proteins 0.000 claims abstract description 16
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 16
- 241000133134 Saussurea Species 0.000 claims abstract description 14
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 229920001436 collagen Polymers 0.000 claims abstract description 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 10
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 10
- 229940016667 resveratrol Drugs 0.000 claims abstract description 10
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 10
- 150000003384 small molecules Chemical class 0.000 claims abstract description 10
- 210000001215 vagina Anatomy 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 235000013717 Houttuynia Nutrition 0.000 claims description 3
- 240000000691 Houttuynia cordata Species 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 241000972672 Phellodendron Species 0.000 claims description 2
- 241000218691 Cupressaceae Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000003746 solid phase reaction Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 7
- 208000028685 Asherman syndrome Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical group C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000006122 Chenopodium album Species 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种修护宫腔粘膜的组合物及其制备方法,该组合物包括按重量份数计的下述物质:α1‑15c生物复合酶9‑15份、鱼腥草提取液3‑5份、益母草提取液5‑7份、黄柏提取液5‑7份、苦参提取液1‑1.5份、壳聚糖碘2‑2.5份、胶原蛋白1‑1.5份、氨基酸碘1.5‑1.8份、雪莲花提取液1‑1.3份、EGF修复因子1‑2份、白藜芦醇1‑2份、小分子保湿剂3‑5份。该组合物针对女性妇科阴道排毒后产生的阴道粘膜及阴道内膜壁的污垢的清除和部分损伤达到及时修复。
Description
技术领域
本发明涉及医药技术领域,尤其涉及一种组合物及其制备方法。
背景技术
目前,全球每年2500-5500万次流产,中国1000万次,年轻未育妇女中有较高的重复人工流产率,其中宫腔粘连是人工流产诸多并发症之一,严重影响女性生育。到目前为止,宫腔粘连的发生率为1.37%,其导致不孕症的因素占到6.3%。
任何引起子宫内膜破环的因素都可能引起宫腔粘连,与妊娠有关的宫腔粘连占91%,常见于自然流产刮宫手术后,以及产后出血刮宫手术后,过度刮宫,将子宫内膜基底层刮掉,目前治疗宫腔粘连的方法一般为宫腔镜疗法,但费用高,且操作不便,对于一些轻度的,比如Ⅰ度、Ⅱ度的宫腔粘连,没有特别有效的药物进行清理。
发明内容
为了解决以上技术问题,本发明提供了一种在清理宫腔粘膜粘连的修护宫腔粘膜的组合物。
为了实现本发明的技术效果,采用了以下技术方案予以实现:
一种修护宫腔粘膜的组合物,该组合物包括按重量份数计的下述物质:α1-15c生物复合酶9-15份、鱼腥草提取液3-5份、益母草提取液5-7份、黄柏提取液5-7份、苦参提取液1-1.5份、壳聚糖碘2-2.5份、胶原蛋白1-1.5份、氨基酸碘1.5-1.8份、雪莲花提取液1-1.3份、EGF修复因子1-2份、白藜芦醇1-2份、小分子保湿剂3-5份。
所述鱼腥草提取液水溶性的鱼腥草提取物、益母草提取液水溶性的益母草提取物、黄柏提取液水溶性的黄柏提取物、苦参提取液水溶性的苦参提提取物、雪莲花提取液为水溶性的雪莲花提取物。
所述壳聚糖碘为固相反应法取得,具体方法如下:
第一步按照质量比将壳聚糖1~6份和碘1份,加入固相反应器中,严密加盖;反应器缓慢旋转20min,使物料混合均匀;
第二步接着缓慢加热到60℃~90℃,之后恒温8~16h;过程中,反应器每隔30~60min作正反交替的旋转运动,直到反应完成为止;
第三步反应结束后,停止反应器旋转,待物料冷却至室温后,出料,过筛,得到的过筛目数为60目以上细粒。
作为进一步的改进,组合物的各物质按照重量份数做如下配比:α1-15c生物复合酶12份、鱼腥草提取液4份、益母草提取液6份、黄柏提取液6份、苦参提取液1.25份、壳聚糖碘2.25份、胶原蛋白1.25份、氨基酸碘1.65份、雪莲花提取液1.15份、EGF修复因子1.5份、白藜芦醇1.5份、小分子保湿剂4份。
本发明还提供了上述所述组合物组合物的应用,将修护宫腔粘膜的组合物用于阴道中。其应用方法为将组合物以液体的形式直接喷于阴道内。
本发明还提供了上述所述组合物组合物的制备方法,所述组合物的制备按照以下工艺步骤:按比例称取α1-15c生物复合酶、鱼腥草提取液、益母草提取液、黄柏提取液、苦参提取液、壳聚糖碘、胶原蛋白、氨基酸碘、雪莲花提取液、EGF修复因子、白藜芦醇、小分子保湿剂于搅拌器中进行搅拌15~20min,混合均匀装瓶即可。
本发明的有益效果如下:
1)本发明组合物,温和,无刺激,不易对阴道产生损害。
2)使用本发明组合物后,针对女性妇科阴道排毒后产生的阴道粘膜及阴道内膜壁的污垢的清除和部分损伤达到及时修复,不仅使用方法简单,对人体不会产生损伤,而且使用效果好。
3)使用本发明组合物后,能够很快排除宫腔内的垃圾,不仅能保持女性生殖系统健康,而且由于宫腔内垃圾和/或盆腔积液排除。
4)使用本发明组合物后,α1-15c生物复合酶可以使卵巢更健康,促进卵巢分泌各种激素,当α1-15c生物复合酶与其他组成物质共同作用于人体,在改善阴道环境的同时促进卵巢分泌各种激素(即使卵巢健康),卵巢健康进而促进女性外生殖器健康,女性外生殖器健康也会促使卵巢更健康,相比于现有技术,能够更快速更有效解决各种妇科问题。同时,盆腔积液和宫腔内垃圾的排除配合α1-15c生物复合酶促进卵巢分泌各种激素,能够使使用者更容易获得性高潮,阴道更紧缩,敏感度更强,能够显著改善性冷淡。
5)本发明组合物,特别是益母草、α1-15c生物复合酶和鱼腥草复配共同作用与人体,能够很快将使用者阴道内的pH调整到3.8-5.0,进而可以杀死和抑制各种有害细菌的增长,恢复女性自洁系统、摆脱妇科疾病的困扰。
具体实施方式
实施例1
一种修护宫腔粘膜的组合物,该组合物包括按重量份数计的下述物质:α1-15c生物复合酶9、鱼腥草提取液3份、益母草提取液5份、黄柏提取液5份、苦参提取液1份、壳聚糖碘2份、胶原蛋白1份、氨基酸碘1.5份、雪莲花提取液1份、EGF修复因子1份、白藜芦醇1份、小分子保湿剂3份。
该组合物制备方法为:
首先:鱼腥草提取液、益母草提取液、黄柏提取液、苦参提取液、雪莲花提取液通过水溶法提取,通过外部购买所得。
其次,壳聚糖碘为固相反应法取得,具体方法如下:
第一步按照质量比将壳聚糖1~6份和碘1份,加入固相反应器中,严密加盖;反应器缓慢旋转20min,使物料混合均匀;
第二步接着缓慢加热到60℃~90℃,之后恒温8~16h;过程中,反应器每隔30~60min作正反交替的旋转运动,直到反应完成为止;
第三步反应结束后,停止反应器旋转,待物料冷却至室温后,出料,过筛,得到的过筛目数为60目以上细粒。
再次次:α1-15c生物复合酶、胶原蛋白、氨基酸碘、、EGF修复因子、白藜芦醇、小分子保湿剂通过外部购买所得。
最后:在氮气环境下,按比例称取α1-15c生物复合酶、鱼腥草提取液、益母草提取液、黄柏提取液、苦参提取液、壳聚糖碘、胶原蛋白、氨基酸碘、雪莲花提取液、EGF修复因子、白藜芦醇、小分子保湿剂置于搅拌器中进行搅拌3min,混合均匀装瓶即可。
该组合物用方法为:将组合物以液体的形式直接喷于阴道内。
实施例2
一种修护宫腔粘膜的组合物,该组合物包括按重量份数计的下述物质:α1-15c生物复合酶15份、鱼腥草提取液5份、益母草提取液7份、黄柏提取液7份、苦参提取液1.5份、壳聚糖碘2.5份、胶原蛋白1.5份、氨基酸碘1.8份、雪莲花提取液1.3份、EGF修复因子2份、白藜芦醇2份、小分子保湿剂5份。
该组合物的制备方法和应用方法与实施例1相同。
实施例3
一种修护宫腔粘膜的组合物,该组合物的各物质按照重量份数做如下配比:α1-15c生物复合酶12份、鱼腥草提取液4份、益母草提取液6份、黄柏提取液6份、苦参提取液1.25份、壳聚糖碘2.25份、胶原蛋白1.25份、氨基酸碘1.65份、雪莲花提取液1.15份、EGF修复因子1.5份、白藜芦醇1.5份、小分子保湿剂4份。
该组合物的制备方法和应用方法与实施例1相同。
其中,实施例3相比于实施例1和实施例2,效果更加。
试用效果
三种实施例中制备的修护宫腔粘膜的组合物的试用效果。
将实施例中制备的组合物用于100个患有宫腔粘膜粘连的患者(Ⅰ度患者和Ⅱ度患者)。
Ⅰ度:多处纤维素样粘连带,两侧宫角及输卵管开口可见,PH值在6-7之间。
Ⅱ度:子宫前后壁致密纤维素样粘连,两侧宫角及输卵管开口可见,PH值在7以上。
PH值正常值在3.5-5之间。
使用本发明的组合物三天后,Ⅰ度患者的PH值平均下降0.3,下降人数比例为90%,Ⅱ度患者的PH值平均下降0.2,下降人数比例为80%.
使用本发明的组合物七天后,Ⅰ度患者的PH值平均下降1,PH值下降到5-6之间,下降人数比例为93%,Ⅱ度患者的PH值平均下降1.2,PH值下降到6-7之间,下降人数比例为87%.
使用本发明的组合物十五天后,Ⅰ度患者的PH值平均下降1.8,PH值下降到5以下,下降人数比例为95%,Ⅱ度患者的PH值平均下降2.6,PH值下降到5-6之间,下降人数比例为90%.
使用本发明的组合物三十天后,Ⅰ度患者的PH值平均下降2.5,PH值下降到3.5-4.2之间,完全处于正常水平,下降人数比例为96%,Ⅱ度患者的PH值平均下降3.4,PH值下降到4.5-5.1之间,接近正常水平,下降人数比例为93%.
使用本发明的组合物六十天后,Ⅱ度患者的PH值平均下降4,PH值下降到3.5-4.5之间,处于正常水平,下降人数比例为97%.
以上所述者,仅为本发明之较佳实施例而已,当不能以此限定本发明实施之范围,即大凡依本发明权利要求及发明说明书所记载的内容所作出简单的等效变化与修饰,皆仍属本发明权利要求所涵盖范围之内。此外,摘要部分和标题仅是用来辅助专利文件搜寻之用,并非用来限制本发明之权利范围。
Claims (7)
1.一种修护宫腔粘膜的组合物,其特征在于,该组合物包括按重量份数计的下述物质:α1-15c生物复合酶9-15份、鱼腥草提取液3-5份、益母草提取液5-7份、黄柏提取液5-7份、苦参提取液1-1.5份、壳聚糖碘2-2.5份、胶原蛋白1-1.5份、氨基酸碘1.5-1.8份、雪莲花提取液1-1.3份、EGF修复因子1-2份、白藜芦醇1-2份、小分子保湿剂3-5份。
2.如权利要求1所述的修护宫腔粘膜的组合物,其特征在于,组合物的各物质按照重量份数做如下配比:α1-15c生物复合酶12份、鱼腥草提取液4份、益母草提取液6份、黄柏提取液6份、苦参提取液1.25份、壳聚糖碘2.25份、胶原蛋白1.25份、氨基酸碘1.65份、雪莲花提取液1.15份、EGF修复因子1.5份、白藜芦醇1.5份、小分子保湿剂4份。
3.如权利要求1所述的修护宫腔粘膜的组合物,其特征在于,所述鱼腥草提取液水溶性的鱼腥草提取物、益母草提取液水溶性的益母草提取物、黄柏提取液水溶性的黄柏提取物、苦参提取液水溶性的苦参提提取物、雪莲花提取液为水溶性的雪莲花提取物。
4.如权利要求1所述的修护宫腔粘膜的组合物,其特征在于,所述壳聚糖碘为固相反应法取得,具体方法如下:
第一步按照质量比将壳聚糖1~6份和碘1份,加入固相反应器中,严密加盖;反应器缓慢旋转20min,使物料混合均匀;
第二步接着缓慢加热到60℃~90℃,之后恒温8~16h;过程中,反应器每隔30~60min作正反交替的旋转运动,直到反应完成为止;
第三步反应结束后,停止反应器旋转,待物料冷却至室温后,出料,过筛,得到的过筛目数为60目以上细粒。
5.权利要求1-4任一项所述修护宫腔粘膜的组合物的应用,其特征在于,将权利要求1-4任一项所述的修护宫腔粘膜的组合物用于阴道中。
6.权利要求1-4任一项所述修护宫腔粘膜的组合物的应用,其特征在于,将组合物以液体的形式直接喷于阴道内。
7.一种制备如权利要求1-4所述的修护宫腔粘膜的组合物的方法,其特征在于,所述组合物的制备按照以下工艺步骤:按比例称取α1-15c生物复合酶、鱼腥草提取液、益母草提取液、黄柏提取液、苦参提取液、壳聚糖碘、胶原蛋白、氨基酸碘、雪莲花提取液、EGF修复因子、白藜芦醇、小分子保湿剂于搅拌器中进行搅拌15~20min,混合均匀装瓶即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710319042.5A CN107281473A (zh) | 2017-05-08 | 2017-05-08 | 一种修护宫腔粘膜的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710319042.5A CN107281473A (zh) | 2017-05-08 | 2017-05-08 | 一种修护宫腔粘膜的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107281473A true CN107281473A (zh) | 2017-10-24 |
Family
ID=60094987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710319042.5A Pending CN107281473A (zh) | 2017-05-08 | 2017-05-08 | 一种修护宫腔粘膜的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107281473A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596946A (zh) * | 2004-07-22 | 2005-03-23 | 常春荣 | 皮肤粘膜组织消毒剂及其加工方法 |
CN103113492A (zh) * | 2012-12-20 | 2013-05-22 | 贵州扬生医用器材有限公司 | 一种制备壳聚糖碘的方法 |
CN106110307A (zh) * | 2016-07-21 | 2016-11-16 | 阮伟 | 一种含生物复合酶的组合物及其应用 |
-
2017
- 2017-05-08 CN CN201710319042.5A patent/CN107281473A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596946A (zh) * | 2004-07-22 | 2005-03-23 | 常春荣 | 皮肤粘膜组织消毒剂及其加工方法 |
CN103113492A (zh) * | 2012-12-20 | 2013-05-22 | 贵州扬生医用器材有限公司 | 一种制备壳聚糖碘的方法 |
CN106110307A (zh) * | 2016-07-21 | 2016-11-16 | 阮伟 | 一种含生物复合酶的组合物及其应用 |
Non-Patent Citations (4)
Title |
---|
吴小华: "氨基酸碘液在阴道炎治疗中的应用及效果探析", 《中国医学创新》 * |
曹思佳等: "《微整形注射并发症》", 31 December 2015, 辽宁科学技术出版社 * |
苑振亭等: "《临证中药500味手册》", 28 February 2016, 金盾出版社 * |
金青哲等: "《功能性脂质》", 31 August 2013, 中国轻工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104739842A (zh) | 低剂量雌三醇的用途 | |
GORDAN et al. | A syndrome of gonadal dysgenesis: a variety of ovarian agenesis with androgenic manifestations | |
CN105535867A (zh) | 一种妇科专用的抑菌凝胶剂及制备方法 | |
CN104721418B (zh) | 一种用于治疗妇科炎症的药物组合物及其制备方法与用途 | |
CN107281473A (zh) | 一种修护宫腔粘膜的组合物及其制备方法 | |
CN106729655A (zh) | 一种抑菌凝胶及其制备方法 | |
CN103071096B (zh) | 用于治疗老年性阴道炎的外用制剂及其制备方法 | |
CN110201049A (zh) | 一种抗菌效果好的妇科抗菌液 | |
CN101143174A (zh) | 一种治疗妇女宫颈糜烂的中药配方 | |
CN103381196B (zh) | 治疗宫颈糜烂的组合物及其应用 | |
CN106974893A (zh) | 一种口腔溃疡贴片及其制备方法 | |
CN112870311A (zh) | 一种女性私密处抑菌水凝胶及使用方法 | |
CN102335416A (zh) | 一种治疗猪瘟的复方中药组合物及其制备方法 | |
CN103877452B (zh) | 一种壳聚糖阴道冲洗液及其制备方法 | |
CN103127460B (zh) | 一种用于治疗妇科炎症的中药组合物及其制备方法 | |
CN1965980A (zh) | 速效阴道收缩剂及其制备方法 | |
CN110448615A (zh) | 一种用于治疗妇科炎症的中药组合物、药物及其制备方法 | |
CN104042989A (zh) | 治疗宫颈糜烂的中药组合物 | |
CN104225565B (zh) | 奶牛产后保健中药复方及其口服片剂的制备方法 | |
CN104740181B (zh) | 一种治疗母畜产后胎衣不下的中药配方及其制备方法 | |
CN104825843B (zh) | 一种外用杀精剂及其在制备避孕类产品中的应用 | |
CN106039239B (zh) | 一种治疗女性不孕症的中药制剂、制备方法及其用途 | |
CN107233446A (zh) | 一种医用壳寡糖复合剂敷料及其制备方法 | |
CN107260957A (zh) | 一种口腔溃疡贴片及其制备方法 | |
CN107583050A (zh) | 一种用于治疗宫颈炎的药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171024 |
|
RJ01 | Rejection of invention patent application after publication |